Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

F. Stephen Hodi, Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth F. Grossmann, David F. McDermott, Gerald P. Linette, Nicolas Meyer, Jeffrey K. Giguere, Sanjiv S. Agarwala, Montaser Shaheen, Marc S. Ernstoff, David R. Minor, April K. Salama, Matthew H. Taylor, Patrick A. Ott, Christine Horak, Paul Gagnier, Joel Jiang, Jedd D. WolchokMichael A. Postow

Research output: Contribution to journalArticlepeer-review

600 Scopus citations

Fingerprint

Dive into the research topics of 'Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences